Breaking barriers: new insights into the contribution of the protocadherin-1 (PCDH1) gene in asthma

Martin-Faura Tellez, Grissel

DOI: 10.33612/diss.565603673

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date: 2023

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Protocadherin 1: epithelial barrier dysfunction in asthma and eczema

Grissel Faura Tellez, MSc a,b,c,d, Martijn C. Nawijn, PhD b,c, Gerard H. Koppelman MD, PhD a,c

a University of Groningen, University Medical Center Groningen, Beatrix Children’s Hospital, Department of Pediatric Pulmonology and Pediatric Allergology; b University of Groningen, University Medical Center Groningen, Laboratory of Allergology & Pulmonary Diseases, Department of Pathology & Medical Biology, c GRIAC Research Institute, University of Groningen, University Medical Center Groningen, and d Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

European Respiratory Journal 2014 43: 671-674
CHAPTER 2

Asthma and eczema result from the interaction between genetic susceptibility and environmental exposures. Over the last two decades, genetic studies have led to the identification of multiple susceptibility genes increasing our understanding of the biological pathways leading to these diseases.

Many asthma and eczema susceptibility genes are expressed in epithelial cells of airway mucosa and skin (1). The epithelium constitutes the first line of the defence to allergens and invading microbes. Recently, loss of epithelial integrity has been implicated as an important mechanism leading to both asthma (2) and eczema (3).

In this issue of the European Respiratory Journal, Mortensen and co-workers report the association of genetic variants in the gene encoding Protocadherin-1 (PCDH1) with asthma, wheeze and eczema in (early) childhood in the Danish birth cohort study COPSAC (Copenhagen Studies on Asthma in Childhood). Their studies also suggest a gene-environment interaction of the PCDH1 gene with passive smoke exposure in early childhood in asthma development. These studies expand on previous data reporting a role for PCDH1 polymorphisms in the susceptibility to both asthma (4-7) and eczema (6,8,9). Given the replicated association of PCDH1 with both diseases, this gene might contribute to a biological pathway that constitutes a shared cause for both diseases. Here, we will summarize the cumulative data on PCDH1 polymorphisms in asthma and eczema and make an attempt to interpret these genetic data in light of PCDH1 expression and function as a contributor to epithelial integrity.
Protocadherin 1: epithelial barrier dysfunction in asthma and eczema

In 1993, PCDH1 was originally identified by Sano et al. (10) as Protocadherin-42 and was reported to induce cell adhesion upon ectopic membrane expression in a mouse fibroblast L-cell assay. PCDH1 is a member of the δ1 subfamily of the non-clustered protocadherin genes. PCDH1 is characterised by seven extracellular cadherin (ECs) repeats, a transmembrane domain and three evolutionarily conserved motifs (CM1-3) in the intracellular tail that have been suggested to participate in intracellular signalling processes (11). The PCDH1 gene spans 25 kb on chromosome 5q31-33 and encodes two main transcripts that contain either three or five exons through alternative splicing. The three-exon isoform does not encode the cytoplasmic domains CM1-3 that are present in the five-exon isoform. Recently, a sixth exon and alternative expression of exon 1 were identified in bronchial epithelial cells (12), whereas skin epithelial expression of PCDH1 has not been extensively characterized to date.

In 2009, PCDH1 was identified as a susceptibility gene for bronchial hyper responsiveness (BHR) and asthma in children and adults. Subsequently, PCDH1 was shown to be expressed in epithelial cells of the airway (5,10) and the skin (13). In four genetic association studies on PCDH1 published to date, PCDH1 gene variants were associated with BHR, asthma, eczema, non-allergic childhood asthma, and transient early wheeze (Table 1) (6,8,9). However, in large-scale genome-wide association studies of asthma, such as the GABRIEL consortium study (7), PCDH1 was not reported to be associated, at a genome-wide significance level, with asthma defined as a self-
CHAPTER 2

reported ‘asthma ever’ diagnosis. In our opinion, these contradictory results may be explained by asthma heterogeneity.

Asthma is a chronic heterogeneous disease of the airways with different disease subtypes, characterized by specific onset of respiratory symptoms, such as cough and wheeze. Mortensen et al. (4) report, in a longitudinal analysis of specific disease subtypes, that PCDH1 gene variants were associated with specific temporal episodes of wheezing and coughing symptoms, and with the onset of asthma. Moreover, characteristic respiratory symptom patterns in early childhood such as transient early respiratory symptoms and recurrent troublesome symptoms were associated with different PCDH1 polymorphisms. These specific associations with subphenotypes of the disease may well have been missed in an association analysis with ‘Have you ever had asthma?’ as an outcome parameter.

In summary, while different association analyses identify a variety of genetic signals in the PCDH1 gene, the general picture that starts to emerge indicates that PCDH1 gene function is associated with asthma, BHR and eczema in early life. Importantly, gene by passive smoking interactions were found to be relevant for the association of PCDH1 with asthma in two populations (4,5). These data suggest that the contribution of PCDH1 gene variants to asthma may become evident when studied in the right environmental context. Well-powered, collaborative meta-analyses of cohorts with specific asthma subphenotypes in early life are needed to provide more robust
Protocadherin 1: epithelial barrier dysfunction in asthma and eczema

evidence for these associations (Table 1). Finally, the lack of association with specific or total IgE levels or with allergic asthma (6) suggests that PCDH1 is relevant to non-IgE-mediated mechanisms of disease susceptibility. Consequently, the contribution of PCDH1 to asthma susceptibility appears to be IgE independent (Table 1).

The cumulative data gathered to date indicate that PCDH1 harbours a complexity of genetic signals associated with asthma and eczema that we do not yet fully understand, without a clear dominant polymorphism that is associated with asthma or eczema in most studies. In order to understand the interrelation of these associations observed for the different PCDH1 single-nucleotide polymorphisms (SNPs), we considered the possibility of linkage disequilibrium (LD) between these SNPs. LD is defined as the preferential occurrence of specific combinations of SNPs in the population, due to their co-inheritance as a result of their close physical proximity. In a recent study in a German population, Toncheva et al. (6) investigated the possibility that associations of PCDH1 with asthma were caused by LD with the nearby cytokine cluster on chromosome 5q31-33, but this was not the case. Our analysis of the LD pattern in Caucasian subjects did not reveal strong evidence for LD between the various SNPs (Figure 1), indicating that these SNPs do not represent a single genetic signal, but apparently make individual, independent contributions to disease susceptibility.

Another explanation for the identification of multiple PCDH1 SNPs to be independently associated with asthma and eczema in different
studies is the presence of multiple SNPs within the \textit{PCDH1} gene that have diverse functional effects. Firstly, very specific SNPs might interact with environmental factors such as passive smoke exposure. Secondly, other SNPs may have more generic effects, for instance, by regulating \textit{PCDH1} gene expression. It is important to realize that the SNPs tested in the original study by Koppelman \textit{et al.} (5) were only situated in coding regions of the gene. Over the past years, it has become increasingly clear that non-coding SNPs can have important regulatory effects on gene expression (by acting as expression quantitative trait locus eQTLs)). The current publication by Mortensen \textit{et al.} (8) adds the association of further non-coding \textit{PCDH1} polymorphisms to asthma and eczema (Table 1), whereas none of the initial associations were replicated in this study. Thus, eQTL studies on these \textit{PCDH1} SNPs in lung and skin tissue are therefore urgently needed to assess their functional relevance. Thirdly, coding SNPs may have generic effects by affecting PCDH1 protein function. The coding SNP Ala514Thr maps to an EC domain in the PCDH1 protein, which is compatible with a potential effect on cell-cell adhesion that needs further study. So far, no data are available on the functional effects of any of the asthma- and eczema-associated SNPs. Finally, adding to the complexity of \textit{PCDH1}, its expression is also probably regulated by epigenetic mechanisms that include gene methylation, given the identification of exon 1A as a CpG Island that is potentially methylated (12).

So, how does PCDH1 contribute to both asthma and eczema? We hypothesize that PCDH1 dysfunction contributes to the defect in
Protocadherin 1: epithelial barrier dysfunction in asthma and eczema

epithelial barrier function observed in both asthma and eczema by regulating the process of epithelial cell differentiation and/or repair. PCDH1 mRNA and protein expression is strikingly upregulated during primary bronchial epithelial cell differentiation, suggesting a role for PCDH1 in achieving or maintaining terminal differentiation of the airway epithelium (12). The regulation of PCDH1 expression in the skin during epidermal differentiation has not been characterized to date, although PCDH1 expression is markedly induced in primary keratinocytes late during the repair process after scratch wounding (13). A similar role in epidermal differentiation has been previously identified for multiple eczema genes in genetic studies. All in all, we propose a role for PCDH1 in epithelial differentiation and repair in both asthma and eczema.

PCDH1 is capable of intracellular signalling. Downstream pathways or PCDH1 interaction partners relevant to asthma or eczema pathogenesis have not been reported to date. Moreover, data on the differential expression of PCDH1 in asthma or eczema versus healthy controls are still lacking. Future studies are needed, that can validate the functional role of PCDH1 in asthma and eczema by controlled experimental approaches, such as small interfering RNA or genetically engineered mouse models, that are currently being developed. These studies also need to address the possibility of environmental exposures affecting PCDH1 expression, with cigarette smoke exposure being of particular interest. Clearly, more studies are needed to resolve the functional effects of PCDH1 SNPs and their relevance for airway and skin epithelial cell biology. These studies
will ultimately validate the initial genetic findings and perhaps provide clues for future novel therapeutic interventions in asthma and eczema.

**Figure 1.** Protocadherin-1 gene, single-nucleotide polymorphism (SNP) position and linkage disequilibrium (LD) pattern: position on reference contig NT_AC094107.3 (*Homo sapiens*) based on genomic data. LD plots are displayed in r^2^ values. The stronger the LD, the darker the squares. r^2^=0 is white and r^2^=1 is represented in black. LD plots were constructed with Haplovew (version 4.2) software using SNP data from the HapMap Project ([http://hapmap.ncbi.nlm.nih.gov/](http://hapmap.ncbi.nlm.nih.gov/)) for the CEU population. Bold type represents SNPs that also appear in table 1.
Protocadherin 1: epithelial barrier dysfunction in asthma and eczema
Table 1. Associations of PCDH1 SNPs with asthma and eczema

<table>
<thead>
<tr>
<th>#</th>
<th>SNP</th>
<th>Location &amp; Function</th>
<th>MAF</th>
<th>Risk Allele</th>
<th>Population / Cohort</th>
<th>Phenotype</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>rs6888135</td>
<td>Intron</td>
<td>C=0.467</td>
<td>A</td>
<td>COPSAC</td>
<td>Asthma (0-7 yr.) + Transient TLS + ETS</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>rs10063472</td>
<td>Intron</td>
<td>T=0.198</td>
<td>T</td>
<td>COPSAC</td>
<td>Transient early respiratory symptoms phenotype (TLS-early) plus ETS</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>rs3822357</td>
<td>Exon 2 - Missense Ala514Thr</td>
<td>T=0.091</td>
<td>G</td>
<td>Children-Tucson, US.</td>
<td>BHR (Methacholine)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G</td>
<td>Southampton, UK.</td>
<td>BHR (Methacholine)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>G</td>
<td>Southampton, UK.</td>
<td>BHR (Methacholine) plus ETS interaction</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A</td>
<td>PIAMA</td>
<td>Eczema-protective based on ISAAC questionnaire</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>rs3797054</td>
<td>Exon 2 - Synonymous Ala750Ala</td>
<td>G=0.373</td>
<td>T</td>
<td>Dutch families</td>
<td>BHR (Histamine)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dutch families</td>
<td>Asthma (doctor diagnosis)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Children-Tucson, US.</td>
<td>BHR (Methacholine)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Vlagtwedde-Vlaardingen</td>
<td>BHR (Histamine)</td>
<td>5</td>
</tr>
</tbody>
</table>
Protocadherin 1: epithelial barrier dysfunction in asthma and eczema

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Population / Cohort</th>
<th>Phenotype</th>
<th>Location &amp; Function</th>
<th>Risk Allele</th>
<th>MAF</th>
<th>SNP</th>
<th>Location / Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>MAGICS and ISAAC</td>
<td>Asthma</td>
<td>Intron</td>
<td>A</td>
<td>A=0.169</td>
<td>rs11167761</td>
<td>Intron</td>
</tr>
<tr>
<td>4</td>
<td>COPSAC</td>
<td>Atopic dermatitis</td>
<td>Exon 3-3' UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs2974704</td>
<td>Exon 3-3' UTR</td>
</tr>
<tr>
<td>5</td>
<td>Dutch families</td>
<td>BHR (Histamine)</td>
<td>IVS3-116 UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs7719391</td>
<td>Intron</td>
</tr>
<tr>
<td>5</td>
<td>Case control, US.</td>
<td>BHR (Methacholine)</td>
<td>Exon 3-3' UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs7719391</td>
<td>Intron</td>
</tr>
<tr>
<td>5</td>
<td>Case control, US.</td>
<td>Asthma (doctor diagnosis)</td>
<td>IVS3-116 UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs7719391</td>
<td>Intron</td>
</tr>
<tr>
<td>8</td>
<td>PIAMA</td>
<td>Asthma based on UKWP</td>
<td>Exon 3-3' UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs7719391</td>
<td>Intron</td>
</tr>
<tr>
<td>8</td>
<td>PIAMA</td>
<td>Eczema based on ISAAC questionnaire</td>
<td>IVS3-116 UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs7719391</td>
<td>Intron</td>
</tr>
<tr>
<td>6</td>
<td>KOALA and PIAMA</td>
<td>Atopic dermatitis</td>
<td>IVS3-116 UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs7719391</td>
<td>Intron</td>
</tr>
<tr>
<td>6</td>
<td>MAGICS and ISAAC II</td>
<td>Asthma protective (doctor diagnosis)</td>
<td>IVS3-116 UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs7719391</td>
<td>Intron</td>
</tr>
<tr>
<td>6</td>
<td>MAGICS</td>
<td>Non-atopic asthma</td>
<td>IVS3-116 UTR</td>
<td>Del</td>
<td>TTC=0.0</td>
<td>rs7719391</td>
<td>Intron</td>
</tr>
</tbody>
</table>

SNP: Single Nucleotide Polymorphism
MAF: Minor Allele Frequency
Risk Allele: The allele associated with increased risk
Phenotype: The condition or disease being studied
Location & Function: The location and functional impact of the SNP
Population / Cohort: The population or cohort from which the data was collected
Definition of abbreviations: PCDH1: protocadherin-1; SNP: single nucleotide polymorphism; MAF: minor allele frequency; rs: reference SNP; COPSAC: Copenhagen Studies on Asthma in Childhood; TLS: troublesome lung symptoms; ETS: environmental tobacco smoke; BHR: bronchial hyperresponsiveness; MAGICS: Multicentre Asthma Genetics in Childhood Study; PIAMA: Prevention and Incidence of Asthma and Mite Allergy; UKWP: UK Working Party; ISAAC: International Study of Asthma and Allergies in Childhood; Del: deletion. MAF was obtained from dbSNP. Risk allele tested for association varied in different cohorts. #: only in Dutch population.

Acknowledgements

Grissel Faura Tellez is supported by a grant from the University Medical Centre Groningen and the University of Southampton. This work was supported by the Netherlands Asthma Foundation grant 3.2.09.055 and MEDALL, a collaborative project supported by the European Union under the Health Cooperation Work Programme of the 7th Framework programme (grant agreement number 261357).
References

1. Lambrecht BN, Hammad H. Death at the airway epithelium in asthma. Cell Res 2013 May;23(5):588-589


